Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heweiyangxue for chemotherapy-related gastrointestinal reactions in lung cancer
ChiCTR2400083612Phase 2Not yet recruiting
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastrointestinal toxicity and non-small cell lung cancer (NSCLC) comparing Chemotherapy + Heweiyangxue Granules with Chemotherapy + placebo granules (2 arms). Primary endpoint: MD Anderson Symptom Inventory-Traditional Chinese Medicine (MDASI-TCM). Planned start May 2024; status: not yet recruiting.
02
Drugs
Heweiyangxue
03
Conditions
gastrointestinal toxicitynon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083612.